Korea's Boryung Takes Hypertension Drug Kanarb Beyond Korea With Stendhal Deal
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Boryung Pharma signed a licensing agreement with Stendhal International, a Mexico-based company, to supply the South Korean company's angiotensin receptor blocker Kanarb (fimasartan) for $22.6 million, marking the first time Kanarb will be sold outside of Korea